Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-009 in Advanced Neuroendocrine Tumors
NCT03670030Phase 2Terminated
- Start
- Nov 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in Neuroendocrine Neoplasm (NEN), gastroenteropancreatic neuroendocrine tumor (GEP-NET), Lung Neuroendocrine Tumor. Started Nov 2018; status: terminated.
02
Drugs
sirolimus
03
Conditions
Neuroendocrine Neoplasm (NEN)gastroenteropancreatic neuroendocrine tumor (GEP-NET)Lung Neuroendocrine Tumor
Beyond the preview
Go deeper on NCT03670030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03670030.